A β3 adrenoceptor agonist plays an important regulatory role in stimulation of thermogenesis and lipolysis and it appears to have anti-ulcer and spasmolytic effects. So the present aim was to examine the effect of BRL 37344 (a selective B3 adrenoceptor agonist) on reflux esophagitis.
Forty-eight rats were divided into twelve sham-operated rats and thirty-six rats with induced reflux esophagitis (RE), which were divided into either RE alone or pretreated with BRL 37344 and/or omeprazole with or without indomethacin. RE was induced in rats, then gastric acid output, pH, plasma nitric oxide (NO), esophageal PGE2, malondialdehyde (MDA) and reduced glutathione (GSH) were measured and the esophageal injury was assessed by macroscopic damage score.
Pretreatment with BRL significantly increased plasma NO, GSH, decreased acid output, esophageal MDA and esophageal injury in comparison to pretreatment. In addition, there was a no significant increase in esophageal PGE2.
It can be concluded that BRL 37344 has an anti-oxidant protective effect in rats with RE.
Adami M , Coruzzi G, Sotirov E, Bertini S, Soldani G: Pharmacological evidence for β3 adrenoceptors in the control of rat gastric acid secretion. Dig. Dis. Sci. 48 (2), 334–339 (2003)
Arch JR , Kaumann AJ: Beta 3 and atypical beta adrenoceptors. Med. Res. Rev. 13 (6), 663–729 (1993)
Aste H , Bonelli L, Ferraris R, Conio M, Lapertosa G: Gastrooesophageal reflux disease; Relationship between clinical and histological features. Dig. Dis. Sci. 44 (12), 2412–2418 (1999)
Bahl AK , Clayton NM, Coates J, Martin DP, Oakley IG, Strong P, Trevethick MA: Comparison of the profiles of agonists as stimulants of the beta 3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat. Br. J. Pharmacol. 117 (3), 580–586 (1996)
Bandyopadhyay D , Bandyopadhyay A, Das PK, Reiter RJ: Melatonin protects against gastric ulceration and increases the efficacy of ranitidine and omeprazole in reducing gastric damage. J. Pineal. Res. 33 (1), 1–7 (2002)
Barbier M , Attoub S, Joubert M, Bado A, Laboisse C, Cherbut C, Galmiche J: Proinflammatory role of leptin in experimental colitis in rats: Benefit of cholecystokinin-B antagonist and B 3-agonist. Life Sci. 69 (5), 567–580 (2001)
Bell NJ , Burget D, Howden CW, Wilkinson J, Hunt RH: Appropriate acid suppression for the management of gastro esophageal reflux disease. Digestion 51 (Suppl. 1), 59–67 (1992)
Biancani P , Sohn UD, Rich HG, Harnett KM, Behar J: Signal transduction pathways in esophageal and lower esophageal sphincter circular muscle. Am. J. Med. 103 (5A), 23S–28S (1997)
Biswas K , Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK: A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J. Bio. Chem. 278 (13), 10993–11001 (2003)
Buege JA , Aust SD: Microsomal lipid peroxidation. Methods Enzymol. 52, 302–310 (1978)
Coman OA , Paunescu H, Ghita I, Coman L, Badaru A, Fulga I: Beta 3 adrenergic receptors: molecular, histological, functional and pharmacological approaches. Rom. J. Morphol. Embryol. 50 (2), 169–179 (2009)
Hirschowitz BI : A critical analysis, with appropriate controls, of gastric and pepsin secretion in clinical esophagitis: Gastroenterology 101 (5), 11149–1158 (1991)
Horinouchi T , Tanaka Y, Koike K: Beta 3-adrenoceptor mediated relaxation of guinea-pig gastric funds smooth muscle: cAMP-independent characteristics and a primary role of 4-aminopyridine-sensitive voltage-dependent K+ (Kv) channels. Nihon Yakurigaku Zasshi 120 (1), 109P–111P (2002)
Horn J : The proton-pump inhibitors: similarities and differences. Clin. Ther. 22 (3), 266–280 (2000)
Kato S , Kitamura M, Korolkiewicz RP, Takeuchi K: Role of nitric oxide in regulation of gastric acid secretion in rats: effects of NO donors and NO synthase inhibitor. Br. J. Pharmacol. 123, 839–846 (1998)
Kobayashi T , Ohta Y, Inui K, Yoshino J, Nakazawa S: Protective effect of omeprazole against acute gastric mucosal lesions induced by compound 48/80, a mast cell degranulator, in rats. Pharmacological Research 46 (1), 75–84 (2002)
Konturek SJ , Zayachkivska O, Havryluk XO, Brzozowski T, Sliwowski Z, Pawlik M, Konturek PC, Cześnikiewicz-Guzik M, Gzhegotsky MR, Pawlik WW: Protective influence of melatonin against acute oesophageal lesions involves prostaglandins, nitric oxide and sensory nerves. J. Physiol. Pharmacol. 58 (2), 361–377 (2007)
Kvietys PR , Twohig B, Danzell J, Specian RD: Ethanol-induced injury to the rat gastric mucosa: Role of neutrophils and xanthine oxidase-derived radicals. Gastroenterology 98 (4), 909–920 (1990)
Lahiri S , Singh P, Singh S, Rasheed N, Palit G, Pant KK: Melatonin protects against experimental reflux esophagitis. J. Pineal. Res. 46 (2), 207–213 (2009)
Larsson H , Mattson H, Sundell G, Carlsson E: Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo. Scand. J. Gastroenterol. 108 (suppl), 23–35 (1985)
Min YS , Lee SE, Hong ST, , Kim HS, Choi BC, Sim SS, Whang WK, Sohn UD: The inhibitory effect of quercetin-3-O-beta-D-glucuronopyranoside on gastritis and reflux esophagitis in rats. Korean J. Physiol. Pharmacol. 13 (4), 295–300 (2009)
Modlin IM , Sachs G (2004): Acid related diseases: Biology and treatment. Lippincott Williams & Wilkins, Philadelphia, USA
Nakamura K , Ozawa Y, Furuta Y, Miyazaki H: Effects of sodium polyacrylate (PANa) on acute esophagitis by gastric juice in rats. Jpn. J. Pharmacol 32 (3), 445–456 (1982)
Okabe S , Takinami Y, Iwata K, Yanagawa T: Mucosal protective effect of leminoprazole on reflux esophagitis induced in rats. Jpn. J. Pharmacol. 69 (4), 317–323 (1995)
Paul A , Patel S, Sevak R, Goswami S, Santani D: Anti-ulcer and gastric inhibitory activity of Z 7114, a B3-adrenoceptor agonist in rats. Indian J. Pharm. Sci. 63 (5), 413–418 (2001)
Poplawski C , Sosnowski D, Szaflarska-Popławska A, Sarosiek J, McCallum R, Bartuzi Z: Role of bile acids, prostaglandins and COX inhibitors in chronic esophagitis in a mouse model. World J. Gastroenterol. 12 (11), 1739–1742 (2006)
Sachs G , Shin JM, Besancon M, Prinz C: The continuing development of gastric acid pump inhibitors. Aliment. Pharmacol. Ther. 7 (Suppl. 1. 4–12), 29–31 (1993)
Sachs G : Proton pump inhibitors and acid-related diseases. Pharmacotherapy 17 (1), 22–37 (1997)
Sarma DN , Banwait K, Basak A, Dimarino AJ, Rattan S: Inhibitory effect of 3-adrenoceptor agonist in lower esophageal sphincter smooth muscle: in vitro studies. J. Pharmacol. Exp. Therap. 304 (1), 48–55 (2003)
Suzuki M , Mori M, Miura S, Suematsu M, Fukumura D, Kimura H, Ishii H: Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic. Biol. Med. 21 (5), 727–731 (1996)
Vasina V , Abu-gharbieh E, Barbara G, De Giorgio R, Colucci R, Blandizzi C, Bernardini N, Croci T, Del Tacca M, de Ponti F: The β3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterol. Motil. 20 (9), 1030–1041 (2008)
Watanabe T , Higuchi K, Tominaga K, Fujiwara Y, Arakawa T: Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta. Gut 48 (6), 774–781 (2001)
Wetscher GJ , Perdikis G, Kretchmar DH, Stinson RG, Bagchi D, Redmond EJ, Adrian TE, Hinder RA: Esophagitis in Sprague-Dawley rats is mediated by free radicals. Dig. Dis. Sci. 40 (6), 1297–1305 (1995)
Wolfe MM , Sachs G: Acid suppression: optimizing therapy for gastro duodenal ulcer healing, gastro-esophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 112 (2 Suppl. 1), S9–S31 (2000)